This Metastatic Colorectal Cancer (mCRC)- Epidemiology Forecast-2032 report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Study Period: 2019-2032
The mCRC epidemiology report gives a thorough understanding of mCRC by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
CRC that spreads, or metastasizes, to the lungs, liver, or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer in the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.
Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one's children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.
Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.
If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.
The first and foremost step in evaluating, Patients can present with a wide range of signs and symptoms such as occult or overt rectal bleeding, change in bowel habits, anemia, or abdominal pain. However, CRC is largely an asymptomatic disease until it reaches an advanced stage. By contrast, rectal bleeding is a common symptom of both benign and malignant causes. Therefore additional risk factors might be needed to help identify those people who should undergo further investigation by colonoscopy. New-onset rectal bleeding should generally prompt colonoscopy in individuals aged 45 years or older. In younger patients, additional factors are used to identify those at highest risk for CRC (e.g., having a family history of CRC, change in bowel habits, unexplained weight loss, and blood mixed with the stool as opposed to blood on the surface of the stool).
For diagnosing CRC, colonoscopy is the method of choice. Colonoscopy identification of advanced lesions is relatively straightforward, but early CRCs might appear as very subtle mucosal lesions (e.g., an innocuous flat laterally spreading polyp), imaging, laboratory, pathology, biopsy, blood test, tumor based tests, etc.
The epidemiology section provides insights about the historical and current mCRC patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides a historical as well as forecasted mCRC epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total incident cases of mCRC were 241,115 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted mCRC epidemiology [segmented as Total Incident Cases of CRC and Total Incident Cases of mCRC] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the mCRC epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
To keep up with the current mCRC patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the mCRC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Metastatic Colorectal Cancer mCRC Understanding
The mCRC epidemiology report gives a thorough understanding of mCRC by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
CRC that spreads, or metastasizes, to the lungs, liver, or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer in the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.
Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one's children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.
Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.
If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.
Diagnosis
The first and foremost step in evaluating, Patients can present with a wide range of signs and symptoms such as occult or overt rectal bleeding, change in bowel habits, anemia, or abdominal pain. However, CRC is largely an asymptomatic disease until it reaches an advanced stage. By contrast, rectal bleeding is a common symptom of both benign and malignant causes. Therefore additional risk factors might be needed to help identify those people who should undergo further investigation by colonoscopy. New-onset rectal bleeding should generally prompt colonoscopy in individuals aged 45 years or older. In younger patients, additional factors are used to identify those at highest risk for CRC (e.g., having a family history of CRC, change in bowel habits, unexplained weight loss, and blood mixed with the stool as opposed to blood on the surface of the stool).
For diagnosing CRC, colonoscopy is the method of choice. Colonoscopy identification of advanced lesions is relatively straightforward, but early CRCs might appear as very subtle mucosal lesions (e.g., an innocuous flat laterally spreading polyp), imaging, laboratory, pathology, biopsy, blood test, tumor based tests, etc.
Metastatic Colorectal Cancer (mCRC) Epidemiology
The epidemiology section provides insights about the historical and current mCRC patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted mCRC epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total incident cases of mCRC were 241,115 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted mCRC epidemiology [segmented as Total Incident Cases of CRC and Total Incident Cases of mCRC] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Metastatic Colorectal Cancer mCRC Epidemiology
The epidemiology segment also provides the mCRC epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
KOL-Views
To keep up with the current mCRC patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the mCRC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report
- The report covers the descriptive overview of mCRC, explaining their causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of mCRC.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Total Incident cases of CRC and Total incident cases of mCRC.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence mCRC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for mCRC
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Metastatic Colorectal Cancer mCRC Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- mCRC Epidemiology Segmentation
Key Questions Answered
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of mCRC?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical mCRC patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of mCRC in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about mCRC?
- Out of all 7MM countries, which country would have the highest incident population of mCRC during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the mCRC Disease market
- To understand the future market competition in the mCRC Disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for mCRC Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the mCRC Disease market
- To understand the future market competition in the mCRC Disease market
Table of Contents
1. Key Insights2. Report Introduction5. Epidemiology and Market Methodology7. Recognized Establishments9. Treatment of Patients with Late-stage Colorectal Cancer: ASCO Resource-Stratified Guideline (2020)14. Spanish Society of Medical Oncology (SEOM) clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)16. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancer (2021)19. Publisher Capabilities20. Disclaimer21. About the Publisher
3. Metastatic Colorectal Cancer (mCRC) Market Overview at a Glance
4. Executive Summary of Metastatic Colorectal Cancer (mCRC)
6. Disease Background and Overview
8. Treatment of Metastatic Colorectal Cancer (mCRC)
10. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (2016)
11. National Institute for Health and Care Excellence (NICE) Guidelines: Colorectal Cancer (2020)
12. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM) (2016)
13. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)
15. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines for the treatment of colorectal cancer- 2019
17. Epidemiology and Patient Population
18. Appendix
List of Tables
List of Figures
